川芎嗪联合参麦注射液对慢性心力衰竭合并心肾综合征患者心肾功能的影响  

Effect of Ligustrazine Combined with Shenmai Injection on Heart and Kidney Function in Patients with Chronic Heart Failure and Cardiorenal Syndrome

作　　者：刘怡[1] LIU Yi(Xuzhou Central Hospital,Xuzhou 221009,China)

机构地区：[1]徐州市中心医院,江苏徐州221009

出　　处：《中国医药指南》2020年第28期107-108,121,共3页Guide of China Medicine

摘　　要：目的探讨川芎嗪联合参麦注射液对慢性心力衰竭(CHF)合并心肾综合征(CRS)患者心肾功能的影响。方法选择2017年1月至2019年2月在我院住院治疗的CHF合并CRS患者80例,根据随机数字表法分为对照组和研究组,每组40例。对照组给予常规药物治疗,研究组在常规药物治疗基础上给予川芎嗪联合参麦注射液治疗。比较两组患者治疗前后心功能指标、肾功能指标以及炎性指标。结果治疗后,两组患者左心室射血分数(LVEF)、每搏输出量、B型钠尿肽(BNP)均较本组治疗前明显改善,且研究组患者LVEF、每搏输出量、BNP均优于对照组(P<0.05)。治疗后,两组患者血肌酐、胱抑素C、血尿素氮水平与本组治疗前比较均明显下降,且研究组下降幅度较对照组更明显(P<0.05)。治疗后,两组患者超敏C反应蛋白(hs-CRP)及脂蛋白磷脂酶A2(Lp-PLA2)水平较本组治疗前明显下降,且研究组下降幅度较对照组更明显(P<0.05)。结论CHF合并CRS患者在常规药物治疗基础上加用川芎嗪联合参麦注射液静脉滴注,可进一步改善患者的心肾功能指标。Objective To investigate the eff ect of Ligustrazine combined with Shenmai injection on heart and kidney function in patients with chronic heart failure(CHF)and cardiorenal syndrome(CRS).Methods A total of 80 patients with CHF and CRS who were hospitalized in our hospital from January 2017 to February 2019 were selected and divided into control group and study group according to the random number table method,40 cases in each group.The control group was given conventional drug treatment,and the study group was given Ligustrazine combined with Shenmai injection on the basis of conventional drug treatment.The cardiac function indexes,renal function indexes and infl ammatory indexes of the two groups of patients before and after treatment were compared.Results After treatment,the left ventricular ejection fraction(LVEF),stroke volume,and B-type natriuretic peptide(BNP)of the two groups of patients were signifi cantly improved compared with those before treatment in this group,and the LVEF,stroke volume,and BNP of the study group were better than those that in the control group(P<0.05).After treatment,the blood creatinine,cystatin C,and blood urea nitrogen levels of the two groups of patients were signifi cantly decreased compared with those of the group before treatment in this group,and the decline in the study group was more signifi cant than that of the control group(P<0.05).After treatment,the levels of hypersensitivity C-reactive protein(hs-CRP)and lipoprotein phospholipase A2(Lp-PLA2)in the two groups were signifi cantly lower than those before treatment in this group,and the decline in the study group was more signifi cant than that in the control group(P<0.05).Conclusion In patients with CHF and CRS,the addition of Ligustrazine combined with intravenous infusion of Shenmai injection on the basis of conventional drug therapy can further improve the heart and kidney function indicators of patients.

关 键 词：慢性心力衰竭 心肾综合征 川芎嗪 参麦注射液 心肾功能 

分 类 号：R541.6[医药卫生—心血管疾病]